The August 2026 approval of Tauklarify gives doctors a second tau PET option for adults with cognitive impairment evaluated for Alzheimer's disease. Families facing younger-onset symptoms can compare age eligibility, accuracy, and role before choosing blood testing, imaging, or both. Tau PET imaging is a brain scan that detects tangled tau protein linked to Alzheimer's. Blood tests check amyloid and tau signals in plasma to estimate amyloid risk.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does Tauklarify add to a workup?
- Which blood test fits younger ages?
- When is a tau scan still useful?
- What limits should younger-onset families weigh?
What does Tauklarify add to a workup?
Tauklarify is florquinitau F 18 injection, formerly called MK-6240, for detecting neurofibrillary tangle pathology. NeurologyLive reports that the FDA approved it August 14, 2026 for adults with cognitive impairment evaluated for Alzheimer's disease NeurologyLive approval report. Approval testing used five blinded readers in each of two studies.
Positive agreement was 68% to 88% against cognition plus amyloid-PET reference. Negative agreement was 93% to 99%, with strong reader agreement. A head-to-head study found MK-6240 more sensitive than the earlier tracer flortaucipir. News-Medical, reporting the University of Pittsburgh work, gives AUC 0.93 versus 0.86 and about 23 extra tau-positive cases per 100 tested News-Medical report on the HEAD study.
Which blood test fits younger ages?
Age cutoff matters first for families with symptoms in the 40s and early 50s. Patient Care Online reports that C2N Diagnostics' PrecivityAD2 was cleared August 20, 2026 for symptomatic adults age 40 and older Patient Care Online clearance report. It measures Aβ42/40 plus p-tau217 ratios as an amyloid probability score.
Roche's Elecsys Phospho-Tau 217P Plasma test was cleared for adults 55 and older with cognitive decline. It is a single-biomarker plasma test for rule-in and rule-out use in primary and specialty care. The Alzheimer's Association specialty-care guideline favors plasma tests with at least 90% sensitivity and specificity for confirmatory use.
- Age 40 to 54 with symptoms: PrecivityAD2 meets the cleared younger-onset age range.
- Age 55 and older: either cleared blood test may fit, based on clinic access.
- Need tau location or staging: ask about tau PET after amyloid assessment.
- Need triage before PET or spinal-fluid testing: ask about high-accuracy plasma testing first.
When is a tau scan still useful?
Blood testing estimates amyloid likelihood and helps guide referrals. Tau imaging shows where tau pathology appears and how far it has spread. That spatial detail can clarify diagnosis when history, exam, and amyloid results do not align. In 1,142 symptomatic participants, PrecivityAD2 showed 97.6% positive predictive value and 93.1% negative predictive value versus amyloid PET or spinal-fluid testing.
Strong blood results may reduce the need for added scans in clear cases. Uncertain, mixed, or atypical cases may still need imaging and specialist review. Families can bring symptom timeline, medication list, prior scans, and family history to the visit. Ask what each test would change: referral, diagnosis, treatment eligibility, or trial screening. Choose the test that answers the next decision.
What limits should younger-onset families weigh?
Early-onset disease beginning before age 65 accounts for under 10% of Alzheimer's cases. Of those cases, 10% to 15% involve APP, PSEN1, or PSEN2 mutations, according to the National Institute on Aging genetics fact sheet NIA Alzheimer's genetics fact sheet. Tauklarify is not established for non-Alzheimer tauopathies, so other tau diseases need different workups. Blood tests are not standalone screening tests and need clinical assessment.
Genetic counseling is important when onset is early, family pattern is strong, or inherited risk is a concern. Ask whether the clinic offers confirmatory PET or spinal-fluid testing if blood results fall in an uncertain range. Confirm sample handling, follow-up timing, and who will explain results to the family. Get the next referral placed before leaving.
You Might Also Like
- FDA’s 2026 Tauklarify Tau PET Imaging Approval: How Younger-Onset Alzheimer’s Families Can Compare Testing Options
- Tauklarify Tau PET vs Amyloid PET After the 2026 Approval: How Younger-Onset Alzheimer’s Families Can Compare Testing Options
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How Younger-Onset Alzheimer’s Families Can Compare Testing Options
